Ibrutinib-based therapy superior for younger patients with previously untreated CLL compared with current standard of care

Landscape change with oral proteasome maintenance in multiple myeloma patients

Patient treatment preferences in relapsed/refractory multiple myeloma

The importance of NF-kB pathway in myeloma

Multiple myeloma highlights and more from ASH 2018

Outcomes for patients with disease progression following CD19-specific CAR T-cell therapy

ASH 2018: Expert overview of the latest in CLL, ALL and AML

The benefits of a stem cell transplant after CAR T-cell therapy in paediatric patients

ACT-1: Addition of alemtuzumab to a CHOP backbone for young patients with T-cell lymphoma

ECHELON-2: a large peripheral T-cell lymphoma trial

Inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy

Improving toxicity and outcomes by taking ibrutinib during and after CAR T-cell therapy for relapsed and/or refractory CLL